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Sclerostin, encoded by the SOST gene, works as an inhibitor of the Wnt 
pathway and therefore is an important regulator of bone homeostasis. Due to its 
potent action as an inhibitor of bone formation, blocking sclerostin activity is the 
purpose of recently developed anti-osteoporotic treatments. Two bone specific 
transcription factors, RUNX2 and OSX, have been shown to interact and co-
ordinately regulate the expression of bone-specific genes. Although it has been 
recently shown that sclerostin is targeted by OSX in mice, there is currently no 
information of whether this is also the case in human cells. We have identified 
SP-protein family and AML1 consensus binding sequences at the human SOST 
promoter and have shown that OSX, together with RUNX2, binds to a specific 
region close to the transcription start site. Furthermore, we show that OSX and 
RUNX2 activate SOST expression in a co-ordinated manner in vitro and that 
SOST expression levels show a significant positive correlation with OSX/RUNX2 
expression levels in human bone. We also confirmed previous results showing 
an association of several SOST/RUNX2 polymorphisms with bone mineral 
density.   
 







































































 Bone tissue homeostasis depends on the balance between bone 
destruction (resorption) and bone formation, and requires the coordinate activity 
of three different types of cells: osteoclasts (bone resorbing cells), osteoblasts 
(bone forming cells) and osteocytes (cells detecting mechanical loads applied to 
the bone). The alteration of the coordinate activities of these of cells can lead to   
osteoporosis and other diseases. Osteoporosis is characterized by a low bone 
mineral density (BMD) and alteration of bone microarchitecture, leading to low 
bone resistance and therefore to a higher risk of fracture. The treatment of bone 
fracture due to osteoporosis implies a high cost to public health. Contrary to 
osteoporosis, two other bone dysplasias, sclerosteosis and Van Buchem’s 
disease, are characterized by an increased bone formation [1, 2]. The studies of 
these two diseases led to the discovery of sclerostin, a protein encoded by the 
SOST gene. Sclerosteosis is associated to mutations in the SOST gene that, 
either introduce stop codons or affect SOST gene splicing [3, 4] leading to 
reduced sclerostin levels and increased bone formation, whereas Van Buchem´s 
disease is linked to the deletion of a 52 kb of a noncoding region harbouring the 
SOST ECR5 enhancer[5]. 
 In humans, sclerostin is mainly produced and secreted in vivo by 
osteocytes and other terminally differentiated cells immersed in a mineralized 
matrix (such as cementocytes or hypertrophic chondrocytes) [6]. Sclerostin binds 
to the low-density lipoprotein receptor related proteins 4, 5 and 6 (LRP4/5/6), 
which inhibit the Wnt signalling pathway [7]. Although the role of sclerostin as an 
antagonist of the Wnt pathway has been thoroughly studied, there is currently 
scarce information about the molecular mechanisms and transcription factors 
regulating sclerostin expression in humans. This is largely due to the lack of 
human osteocytic cell lines and the difficulty to obtain primary osteocytes 
cultures. However studies in murine models have revealed that two different 
transcription factors, Runt-related transcription factor 2 (RUNX2) [8] and, more 
recently, Osterix (OSX) [9], regulate sclerostin expression. OSX, also known as 
transcription factor SP7 is an osteoblast-specific transcription factor, belonging to 
the SP/KLF family, known to exert its regulatory function through the binding to 
guanine-rich sequences at specific target genes. On de other hand, RUNX2 is an 




































































sequences located at the promoter regions of its target genes and control their 
transcription. Recently, it has also been shown that RUNX2 can interact with 
OSX, to co-ordinately induce the expression of the COL1A1 gene encoding the 
main component of collagen type I [10]. On the other hand, the importance of 
OSX in bone formation has been highlighted by the fact that Osx-null embryos 
completely lack bone formation [11]. Using a murine model, Yang et al. (2010) 
showed that OSX controls the transcriptional levels of Sost through its direct 
interaction with the Sost promoter [9]. It has not been confirmed yet whether this 
gene-gene interaction is preserved in human cells.   
 The binding of regulatory proteins to promoter regions can be affected by 
genetic factors. Single nucleotide polymorphisms (SNPs) can directly alter 
regulatory sequences in the promoter of a given gene and therefore modify the 
expression levels of that gene, the folding of the mRNA or the subcellular 
localization of the protein, which may then influence tissue homeostasis. RUNX2, 
OSX and SOST encode for proteins with an important role in bone homeostasis. 
These three genes also share the fact that they harbour, in their DNA sequences, 
SNPs that have been associated with BMD [12-16]. Indeed, our group, amongst 
others, has shown an association between some SNPs located at the SOST 
promoter and BMD[16]. On the other hand, a recent meta-analysis confirmed a 
relationship between SNPs located at the SOST and OSX promoters and BMD 
[17]. In this current work, we aimed to confirm whether OSX and RUNX2 bind to 
the SOST promoter and regulate SOST expression in humans. Additionally, we 
explored if there was an interaction between the genetic variants of these genes 
on BMD. 
  
MATERIALS AND METHODS 
Plasmids 
Human SOST promoter reporter constructs were generated by PCR and 
subcloned into the pGL2 basic vector. Human RUNX2 expression vector was 
kindly provided by Dr. Svante Paabo. Human OSX expression vector was 
purchased from Origene (Clone OHu19040).  
 




































































The human HEK-293T cell line was transfected with SOST reporter 
vectors, transcription factor expression vectors (or empty control vectors) and a 
-galactosidase control reporter using the Lipofectamine 3000 reagent 
(Thermofisher Scientific, Waltham, MA, USA). After 48 hours, the cells were 
harvested and lysed. Luciferase activity was quantified using the Luciferase 1000 
assay system 45050 (Promega, Madison, WI, USA). Luciferase values were 
normalized using -galactosidase activity measured with Galactosidase Reporter 
Gene Assay System, t1007, (Thermofisher Scientific).  
 
Chromatin Immunoprecipitation 
SaOS-2-derived sclerostin superproducer cells were maintained in culture 
as previously described [18]. Chromatin immunoprecipitation (ChIP) was 
performed using the Red ChIP Kit (Diagenode, Seraing, Belgium) following the 
instructions of the manufacturer. Crosslinked cells were sonicated for 15 cycles 
(30s on/30s off) with the Bioruptor (Diagenode, Seraing, Belgium). The 
antibodies used included anti-RNA Polymerase (H-224 from Santa Cruz 
Biotechnology, Dallas, TX, USA), anti-Osx antibody (ab22552 Abcam, 
Cambridge, UK), anti-Runx2 antibody (d1l7f cell signaling, Danvers, MA, USA) 
and a control antibody against rabbit IgG (SC-2027 Santa Cruz Biotechnology). 
Ten million cells were used for each immunoprecipitation. DNA concentration 
values for each ChIP and input DNA sample were calculated from their 
respective average cycle threshold values in real-time quantitative PCR (qPCR) 
analyses. Graphs represent percentage of input values. All reactions were 




RNA was isolated from trabecular bone samples of the femoral heads of 
patients undergoing hip replacement surgery (n=21) and cDNA synthesis was 
performed as previously described [19]. SOST expression levels were measured 
by qPCR using the Taqman assay Hs00228830_m1 (Thermofisher Scientific). 
Analysis of the expression of OSX and RUNX2 was performed using the Exiqon 




































































relative to the housekeeping gene encoding TATA Box Binding Protein (TBP) as 
2−Δct. Primer sequences are available upon request. 
 
Genetic association analysis 
We wanted to analyse if there is an interaction between different 
polymorphisms in these three genes, SOST, RUNX2 and OSX, that have been 
previously associated to variations in BMD. In brief, we selected a group of 987 
postmenopausal women (either healthy controls or women with primary 
osteoporosis) and lumbar spine BMD was measured with a Hologic QDR 4500 
densitometer. We analysed the following SNPs: SOST, rs851056; RUNX2, 
rs2819854 and rs7771980; OSX, rs2016266. All have been associated with 
skeletal traits in previous studies [14, 15, 17, 20]. They were analysed by using 




Quantitative data are expressed as mean±SEM. Statistical comparisons of 
data sets were performed with the two-tailed Student’s t test. The correlations of 
gene expression levels were assessed using the Pearson´s correlation 
coefficient after log-transformation of the relative expression values. BMD values 
were adjusted for age and weight. Differences were considered significant when 




Osterix targets SOST gene in humans 
 In order to determine if endogenous Osterix binds to the native SOST 
promoter in humans, we performed ChIP experiments. Since sclerostin 
expression is rarely detected in human osteoblasts, we used an osteoblastic cell 
line, previously characterized by our group, that produces high levels of 
sclerostin, as the source of chromatin [18]. In silico analysis of the promoter 
region of SOST (-1500/+1) showed four putative SP1 binding sites (5´-
(G/T)GGGCGGPuPu(C/T)-3` located at positions -1152, -1145, -317 and -124. 




































































has been previously shown to bind to SP1 consensus sequences [10], we 
designed different oligonucleotide pairs to amplify the regions surrounding these 
putative SP1 binding sites located at the SOST promoter. The region previously 
identified in mouse as an OSX binding site [10] is only partially conserved in the 
human sequence, and no binding site for SP1 is predicted in this specific 
sequence in silico at the human promoter. In addition to OSX, RUNX2 is also 
essential for bone formation. RUNX2 is a sequence-specific transcription factor 
that recognizes the sequence 5´-PuACCPuCA-3´or its complementary sequence 
[21, 22]. This sequence is likewise recognized for other members of the Runt-
related transcription family proteins, and is generally known as AML1 putative 
binding site. Besides the four putative SP1 binding sites, the in silico analysis 
also detected three putative AML1 binding sites (-1044, -752, -323), one of them 
located near  the predicted SP1 site at position -317 (Figure 1A, upper panel). 
We therefore decided to perform an additional ChIP analysis using anti-RUNX2 
antibodies, in order to confirm the binding of RUNX2 to this region of the human 
SOST promoter. We detected a significant level of enrichment when the 
amplification of the fragments pulled down with the RUNX2 and OSX antibodies 
was performed with oligonucleotide pair number 5. This enrichment was also 
significant when using oligonucleotide pair 6 for the amplification, but only when 
the sheared chromatin is pulled down with the anti-RUNX2 antibody (Figure 1A, 
lower panel). According to our results, the DNA region showing high levels of 
enrichment for both OSX and RUNX2 in the ChIP contains both a putative SP-
family protein binding site (at -317) and a putative RUNX2 binding site in close 
proximity (at -323), as has been previously shown for the COL1A1 gene in 
human cells[10].  No enrichment was detected when the DNA pulled down was 
amplified with oligonucleotide pairs 3 and 4, suggesting that the putative AML1 
binding site located at -752 is not actually functional. A low level of enrichment for 
both OSX and RUNX2, although not statistically significant, was also detected in 
the 5´end of the promoter sequence, analysed using oligonucleotide pair 2 
(Figure 1A, lower panel). Although this enrichment was not significant and the 
two target sequences for RUNX2 and OSX are located farther apart from each 
other than those located in a more proximal position, we cannot completely 
discard a possible binding of these two proteins to their putative target sites 




































































human SOST transcription.  However, our results clearly indicate that, similarly to 
what has been shown in mice, both OSX and RUNX2 bind to the promoter of the 
human SOST gene in a region proximal to the transcription start site (TSS). As 
an additional control to assess the performance of the procedure, a parallel 
immunoprecipitation using an antibody against a structural Histone (Histone H3) 
was used at all points (Figure 1, lower panel). 
 
RUNX2 and OSX co-operatively regulate the expression of human 
sclerostin 
 Having established that both RUNX2 and OSX bind to the promoter of the 
human SOST gene, our next goal was to study whether these two proteins 
functionally interact and regulate SOST expression in human cells as has been 
shown for the COL1A1 gene. To this end, we produced a reporter vector carrying 
the firefly luciferase gene under the control of the human SOST promoter (-
1440/+1). This construct was used to transfect the human HEK-293T cell line, 
with or without OSX- and RUNX2-expression vectors and the corresponding 
controls. Our results (Figure 2A) show that both RUNX2 and OSX significantly 
stimulated the human SOST promoter, leading to an increase in the reporter 
gene expression. Interestingly, there was an additive effect when both 
transcription factors were transfected, which enhanced luciferase activity 1.5-fold 
in comparison with the effect of each individual transcription factor (Figure 2A). 
 
Expression of SOST, OSX and RUNX2 in human bone 
In order to explore whether the results obtained with the reporter vectors 
reflected the situation in vivo, we analysed the expression of RUNX2, OSX and 
SOST in human bone. Although there was a high variability between samples 
regarding the expression levels of the three genes, we found a significant 
positive correlation between the expression levels of OSX and SOST (r=0.55, 
p=0.01) and also between the expression levels of RUNX2 and SOST (r=0.47, 
p=0.03) (Figure 2B). On the contrary, as expected, there was no correlation 
between OSX and RUNX2 expression levels (r=0.19, p=0.43) (Figure 2B).  
 





































































We wanted to analyse if there was an interaction between several  
polymorphisms of these three genes, SOST, RUNX2 and OSX, that have been 
previously associated to variations in BMD. All genotypes were consistent with 
Hardy-Weinberg equilibrium. OSX alleles were not significantly associated with 
BMD (Table 1). Both RUNX2 alleles showed a trend for association with age and 
weight-adjusted BMD (rs2819854, p=0.04; rs7771980, p=0.09). These loci are 
located 15.2 kb apart and are in strong linkage disequilibrium. Nevertheless, 
when alleles at both loci were combined into a single score, the number of risk 
alleles (the minor alleles) showed a linear trend for association with BMD. Thus, 
the average lumbar spine BMD values for women with 0,1,2 or ≥3 risk alleles 
were 0.890±0.008, 0.865±0.007, 0.873±0.009 and 0.822±0.023 g/cm2, 
respectively (p=0.022). The previously reported association of the rs851056 
polymorphism of the SOST promoter with BMD was confirmed. However, no 
statistically significant interaction between SOST and RUNX alleles was found. 
 
DISCUSSION 
In the present work, we aimed to explore the role of OSX in the regulation 
of human SOST expression and its relation with the osteogenic transcription 
factor RUNX2. Our results show that both OSX and RUNX2 bind to the human 
SOST promoter in a region close to its TSS (Figure 1A). A more distal region 
also shows a small level of enrichment, suggesting the existence of additional 
regulatory regions at the human SOST promoter that could also be targeted by 
these two factors. The region that shows a high percentage of enrichment for 
both RUNX2 and OSX harbours indeed two putative SP1 binding sites, 
previously shown to be targeted by OSX [10], one of them closely located to a 
RUNX2 binding site also found in the enriched region (Figure 1A). The close 
proximity of the RUNX2 and OSX binding sites resembles the disposition of the 
confirmed OSX and RUNX2 binding sites at the human COL1A1 promoter [23]. 
Our results further supports the idea that these two factors could bind to adjacent 
sites and also physically interact, as previously demonstrated for the COL1A1 
[10] and osteocalcin genes [24]. Our results provide evidence that RUNX2 and 
OSX similarly induce the activity of the human SOST promoter. Furthermore, 
using a luciferase reporter system, we show that binding of both OSX and 




































































importantly, that the action of these two transcription factors has a cooperative 
effect on SOST transcription, co-ordinately achieving significantly higher SOST 
expression levels that those obtained with the individual expression vectors 
(Figure 2A). These results indicating a crucial role of RUNX2 and OSX in the 
activation of the human SOST gene are further highlighted by the fact that 
expression levels of these two factors are positively correlated with SOST 
expression levels in human bone, as we show in Figure 2B. RUNX2 is already 
expressed in human mesenchymal stem cells, the precursors of cells in the 
osteoblastic lineage, whereas OSX is only expressed once the cells have 
matured into pre-osteoblasts. The subsequent differentiation of the pre-
osteoblasts into the mature osteoblasts would require the concerted action of 
both RUNX2 and OSX. Therefore, in view of these results we suggest that both 
OSX expression and RUNX2 expression, are limiting factors for a correct 
transcriptional activation of the human SOST endogenous gene. We were not 
able to perform ChIP or reporter vector experiments using human osteocytes. 
However, the correlation of SOST and OSX/RUNX2 expression in bone 
fragments (in which osteocytes are the major cellular component) suggests that a 
similar stimulatory interaction between OSX/RUNX2 and SOST indeed takes 
place in human osteocytes. 
There are several forms of RUNX2 transcripts, which depend of two 
different promoters (P1 and P2). Both are active in cells of the osteoblastic 
lineage, but the predominant form may vary with the differentiation stage [13, 25]. 
In this study we found an association of polymorphisms located in the region of 
promoter P2 with BMD. This observation is in line with previous reports showing 
an association of P2 polymorphisms with several skeletal phenotypes [12-14, 26, 
27]. However, the underlying mechanisms have not been elucidated. In view of 
our results, it could be speculated that the polymorphisms regulate the 
transcriptional activity of RUNX2 P2, and consequently, SOST expression. 
Further studies are needed to confirm this concept. Although we confirmed the 
association of RUNX2 and SOST polymorphisms with BMD, we did not find 
statistical evidence for interaction. The relatively small sample size limits the 
power of our study. On the other hand, given the exploratory nature of this study, 
we did not apply multiple test corrections. Therefore, the improved association of 




































































cohorts. Of course, RUNX2 modulates not only SOST but also other genes 
related to bone formation [28, 29], and they could be involved in the association 
of RUNX2 alleles with BMD. It is also possible that other RUNX2 polymorphisms 
in linkage disequilibrium with those studied here are the actual drivers of the 
association.  
Additionally, it is worth noting that the regulation of sclerostin is complex. 
A number of factors, including OSX and RUNX2, shown in this study, but also 
vitamin D, TGF and BMPs act through the binding to motifs in the 5’ region of 
the [30, 31]. However, elements located distal to the SOST gene, such as the 
ECR5 sequence included in the so-called Van Buchem´s region, seem to 
mediate the regulatory effects of factors such as parathryroid hormone and 
MEF2 on sclerostin production [32] 
In conclusion, our results confirm that RUNX2 and OSX modulate the 
transcription of the sclerostin human gene and common RUNX2 polymorphisms 




Figure 1.- RUNX2 and Osterix binding to the human SOST promoter. (A) 
Upper panel depicts SOST promoter region, Exon 1 and Transcription Start Site 
(TSS). Oligonucleotide pairs used for the amplification of the different regions are 
indicated. Solid bars indicate putative biding sites for RUNX2 (black) and OSX 
(grey). Dashed bar indicates the sequence correspondent to Osx biding site in 
mouse (not preserved in the human DNA sequence). Position of each of these 
putative binding sites respect to the TSS is shown.  Left lower Panel shows ChIP 
analysis of RUNX2, OSX binding and RNA Pol II presence at the SOST promoter 
in human primary osteoblasts. Rabbit IgG was used a negative control. Right 
lower panel shows the results of a ChIP analysis performed in parallel, using an 
antibody against histone H3 as a positive control of the procedure. Data was 
obtained by subtracting IgG control values from the corresponding antibody 
values. Graphs represent percentage of input DNA. Graph shows average values 
from three different experiments. Bars represent standard error of the mean 
values. P values are as follows, (***, P≤0.0005; **, P≤0.005; *, P≤0.05). P values 





































































Figure 2.- Association of RUNX2 and OSX with SOST expression. (A) 
Induction of SOST transcriptional activity by binding of OSX and RUNX2 to its 
promoter region. HEK-293T cells were transiently co-transfected with SOST-
proximal promoter reporter vectors and mock or OSX construct and/or RUNX2 
construct for 48h. Luciferase activity was measured and normalized against β-
galactosidase activity. Relative luciferase activities were expressed as 
mean ± SEM of luciferase activity normalized by -galactosidase values from 
four independent experiments. (B) Correlation analysis of mRNA expression of 
SOST/RUNX2, SOST/OSX and RUNX/OSX mRNAs in human bone tissue. 
There was a significant positive correlation between SOST gene expression and 
RUNX2 gene expression. Similarly a positive correlation was found between 
SOST and OSX expression. No significant correlation was found between OSX 
and RUNX2. Gene expression values are shown in relative fluorescence units. 
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SNP GENE ALLELES MINOR ALLELE aMAF bMAF-1000G cHWE-p dp eadj-p 
rs2016266 OSX A>G G 0.340 0.344 0.72 0.259 0.143 
rs2819854 RUNX2 C>T T 0.480 0.475 0.140 0.103 0.042 
rs7771980 RUNX2 C>T C 0.050 0.079 0.75 0.076 0.094 
rs851056 SOST C>G G 0.380 0.414 0.250 0.035 0.032 
Perez-Campo Table 1 
Table 1.- Genetic Association analysis. Interaction between different polymorphisms at the 
RUNX2, OSX and SOST genes.  
 
a MAF: minor allele frequency in this series.  
b MAF-1000G: minor allele frequency in the 1000 Genomes project.  
c HWE-p: p-value of the HWE equilibrium test.  
d P: Unadjusted association with BMD.  
e Adj-p: Age- and weight-adjusted association with BMD.  
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